DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Information source: Dana-Farber Cancer Institute
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mesothelioma

Intervention: Erlotinib (Tarceva, OSI-774) (Drug); Bevacizumab (Avastin) (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Pasi A Janne, MD, PhD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute

Summary

The purpose of this study is to determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.

Clinical Details

Official title: Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma

Study design: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Primary outcome: To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma

Secondary outcome:

To determine the time to tumor progression

to determine the duration of response

to determine the median and overall survival of patients

to determine the safety of the drugs administered

Detailed description: Each cycle of study treatment lasts 21 days. The patient will take erlotinib by mouth once daily. On day 1 of every cycle, the patient will receive bevacizumab intravenously over a 30-90 minute time period.

CT scan(s), MRI(s) and/or x-ray(s) of the cancer site will be performed every 6 weeks (2 cycles) to assess the extent of the response to treatment.

Bloodwork will be performed before the first dose of erlotinib and bevacizumab at Cycle 1, Cycle 2, Cycle 3, and at the end of treatment.

At the completion of the treatment a physical exam, vital signs, blood tests, urine tests and standard radiologic testing will be performed.

The duration of study depends upon how the patients' mesothelioma responds to treatment as well as how well the patient tolerates the medication.

Eligibility

Minimum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Mesothelioma that has been previously treated with at least one chemotherapy regimen

- 18 years of age or older

- Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities

- Four or more weeks since last major surgery

- Four or more weeks since last radiation therapy

- Three or more weeks since last chemotherapy

- Life expectancy of 12 weeks or more

- Blood tests that show kidneys, liver and bone marrow to be working adequately

- Able to comply with study and/or follow-up procedures

Exclusion Criteria:

- Prior exposure to Tarceva (OSI-774, erlotinib), trastuzumab, ZD1839 or C225

- Receiving anticoagulation medication other than low dose Coumadin

- Clinically significant heart disease such as uncontrolled hypertension, previous heart attack within past 12 months, uneven heartbeat, etc.

- History of central nervous system disease such as seizures not controlled with standard medical therapy, brain metastases or history of stroke

- Major surgery within 28 days of screening

- Daily treatment with aspirin or anti-inflammatory medications

- Pregnant or lactating (pertaining to women only)

- Serious or nonhealing wound, ulcer or bone fracture

- Difficulty swallowing

- A disease or disorder that interferes with ability to digest and absorb food

- History of coughing up more than 1/4 teaspoon of blood

- A medical condition that could make it unsafe for patient to participate in this study

Locations and Contacts

The University of Chicago, Chicago, Illinois 60637, United States

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Massachusetts General Hospital, Boston, Massachusetts 02114, United States

Additional Information

Dana-Farber Cancer Institute Lowe Thoracic Oncology Program

Related publications:

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.

Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15;22(16):3238-47.

Starting date: February 2004
Last updated: April 3, 2007

Page last updated: October 19, 2007

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014